In Brief: Ostex International
Ostex International: Robert Glaser joins company as president and chief operating officer. Glaser most recently was with Merck as senior VP-marketing, where he was responsible for all osteoporosis-related products. Seattle-based Ostex discovers and develops diagnostics and therapeutics for skeletal diseases and has agreements with companies including Merck, Wyeth-Ayerst, J&J, Corning Clinical Labs and SmithKline Beecham. Glaser will be replaced at Merck by VP-Marketing Jeremy Allen, who has been with the company since August. Allen also is president of the Merck-affiliated Bone Measurement Institute...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth